SRS vaccine developed
Advanced BioNutrition Corp. (ABN) on Friday announced its strategic partner in Santiago, Chile, has provisionally registered a freeze-dried, oral-powder vaccine to help prevent salmon rickettsial syndrome (SRS) in farmed salmon and trout.
Developed by scientists at Centrovet Laboratories, the vaccine is administered through salmon feed by means of ABN's patented MicroMatrix™ Targeted Delivery Systems (TDS). It can also be delivered orally by injecting immature fish.
SRS outbreaks have cost Chile's salmon farming industry more than USD 100 million (EUR 75 million) in recent years, according to ABN.
"It is expected that the use of the new vaccine, in conjunction with proper disease management, will significantly reduce the losses due to this SRS pathogen," said Centrovet CEO David Farcas. "Importantly, it will also lessen antibiotic use, the subject of much concern in global aquaculture."
"The MicroMatrix TDS is ideally suited to deliver the vaccine to aquaculture applications like this one," added ABN CEO Bill Kirk. "It offers a bona fide breakthrough to fish farmers around the world."
ABN is a privately held nutritional research and development company based in Columbia, Md.